Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823234 | 0.84 | THRB (0.32) | THRBDGAT1 | |
| SCHEMBL8284499 | 0.78 | ELANE (0.34) | ELANEDGAT1 | |
| SCHEMBL12922356 | 0.78 | ELANE (0.34) | ELANEDGAT1 | |
| SCHEMBL291087 | 0.78 | THRB (0.35) | THRB | |
| SCHEMBL31073969 | 0.76 | ELANE (0.33) | ELANEDGAT1 | |
| SCHEMBL56282 | 0.76 | THRB (0.33) | THRB | |
| SCHEMBL5015809 | 0.76 | THRB (0.33) | THRB | |
| SCHEMBL13434035 | 0.76 | GAA (0.42) | THRB | |
| SCHEMBL291088 | 0.76 | ALDH1A1 (0.33) | THRB | |
| SCHEMBL20419337 | 0.74 | ELANE (0.32) | ELANEDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407444-B2 | Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180118764-A1 | ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118764-A1 | ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407444-B2 | Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia | MCL1, PNMT, GNMT | ELANE 1144/4885THRB 1046/4885DGAT1 2003/4885 |
| US-20180118764-A1 | ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | MCL1, PNMT, GNMT | ELANE 1144/4885THRB 1046/4885DGAT1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.